Search results
Stop Spending Tax Dollars on NIH's Cruel Animal Experiments
Newsweek· 3 hours agoProject's (WCW) viral #BeagleGate campaign uncovered that Dr. Fauci's division of the NIH—the...
Earnings call: Ocugen reports progress in gene therapy trials and Q1 financials By Investing.com
Investing.com· 2 hours agoOcugen, Inc. (NASDAQ: NASDAQ:OCGN) discussed significant advancements in its gene therapy programs...
House COVID origins panel accuses Fauci adviser of obstructing probe, subpoenas him for public...
New York Post· 6 days agoMorens still serves as a senior scientific adviser to the director of the National Institute of...
SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Call Transcript May 7, 2024 SIGA...
Why do some people face greater risk from COVID?
Futurity· 5 days agoCollaborators conducted extensive analyses across many different aspects of the immune responses of over 1,000 patients across the country. The...
Individuals of all ages with positive skin or blood test should receive preventive treatment for TB,...
Medical Xpress· 6 days agoPreventive treatment for tuberculosis (TB) can stop latent TB infections from developing into deadly...
Zach Edey’s wildly off-target first pitch left Cubs mascot stunned
New York Post· 6 days agoWhile Edey’s errant throw is worthy of earning a spot on the list of worst first pitches ever, there...
NIH official set to testify before COVID panel on ‘discrepancies’ in pandemic timeline
The Hill via Yahoo News· 5 days agoLawrence Tabak, principal deputy director of the National Institutes of Health (NIH), will testify...
WBEZ and Bookends and Beginnings Present: On Call - An Evening w Dr. Anthony Fauci and Sasha-Ann...
Chicago Sun-Times· 5 days agoWBEZ and Bookends and Beginnings are proud to present Dr. Anthony Fauci on Wednesday, June 26 at...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 12 hours agoAll three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets
